Precision targeting provides new insights into therapy-resistant cancers

March 6, 2017 by Lorena Anderson, University of California - Merced
Precision targeting provides new insights into therapy-resistant cancers
UC Merced researcher Fabian V. Filipp in the lab. Credit: UC Merced Systems Biology and Cancer Metabolism Laboratory

The National Cancer Institute's "cancer moonshot" tasks researchers with, among advancing other new biotechnologies, delving into immunotherapy and epigenomic analysis.

UC Merced professor Fabian V. Filipp is doing his part, further developing his work on precision targeting of cancers and personalized medicine.

Filipp has already mapped the genetic landscape of melanoma and found a drug that could be effective in battling the deadly skin , and has now identified epigenetic master regulators that control cancer published today in Oncotarget, Cancer Metastasis Review, and Oxford Academic Press.

"The essence of precision medicine is to understand, which drug targets are effective given each person's unique genetic and epigenetic makeup," Filipp said.

What many people don't know is that there is more to the genes than what we might see molecularly.

"There is a hidden layer of regulation controlling the activity of genes without changing the core code of our DNA. This field of study is called epigenetics," he said.

Filipp's approach to precision targeting shows that if researchers can regulate hormone receptors and epigenetic factors at the same time, they can control cancer.

"That's why molecular understanding of epigenetic mechanisms underlying the development of cancer is of critical importance," he said.

Professor Fabian V. Filipp working on cancer epigenomics and precision targeting of malignant melanoma at UC Merced Systems Biology and Cancer Metabolism Laboratory. Credit: UC Merced Systems Biology and Cancer Metabolism Laboratory

The 'yin and yang' of cancer

According to latest genomic insights, researchers compare the delicate epigenomic homeostasis to yin and yang: Complementary forces keep each other in check. If one force overtakes the systems is out of equilibrium. For the cells this means either unlimited growth, cancer, or death. Without doubt, once we have a better understanding of epigenomic regulation, we can design drugs that counterregulate these factors.

Today, his research group published several research articles on precision targeting of therapy-resistant cancer, including cover studies in Oncotarget, Springer's Cancer Metastasis Reviews, and Oxford's Briefings in Functional Genomics, as well as recent work in Nature Publishing's Scientific Reports, and Wiley's Pigment Cell Melanoma Research.

Filipp's Systems Biology and Cancer Metabolism Lab in the School of Natural Sciences at UC Merced identified such an epigenetic factor, which the researchers named Jumonji because of its "magic and mysterious roles in cancer and cellular development."

"Epigenomic modifiers have the ability to modulate our genetic readouts—they can emphasize or silence genes," Filipp said. "If an epigenomic modifier is dysregulated in cancer, it might switch on oncogenes (genes that in certain circumstances transform cells into tumor cells) or shut down tumor suppressors. Both events will transform cells into tumor cells. In addition to genomic changes, epigenomic changes also contribute to the ability of cancer cells to evade therapy."

"We are all proud of professor Filipp's accomplishments," Vice Chancellor for Research Samuel Traina said. "He exemplifies the attributes of a great UC professor."

In addition to prolific publishing, Filipp recently delivered guest lectures at the University of Maryland School of Medicine's Greenbaume Cancer Center and the Pan-American Society for Pigment Cell Research's conference entitled "Pigment Cells, Their Responses, and the Generation of Diversity" conference, both in Baltimore, where he chaired a session on melanoma metabolism. He also received several awards recently, including Pan-American Society for Pigment Cell Research's Estela Medrano Young Investigator Award; the University of California Office of the President Cancer Research Coordinating Committee Award and the Margo F. Souza San Joaquin Valley Mentor Leadership Award.

In research science, Filipp is especially concerned with promoting advanced graduate training and student mentoring. Filipp has developed the first advanced training course on , cancer metabolism and metabolic flux analysis for graduate students in the Quantitative Systems Biology group at UC Merced, where he brought guest speakers from Europe. Last year, he promoted hands-on training in cancer systems biology for UC Merced undergraduates and Merced high school students, and plans to do the same this year.

"It is a special fulfilment to foster young careers and see our research talent grow in the Central Valley of California," Filipp said.

Explore further: Epigenetic changes promoting cancer metastasis identified

More information: Stephen Wilson et al. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells, Oncotarget (2017). DOI: 10.18632/oncotarget.15681

OUP accepted manuscript, Briefings in Functional Genomics (2017).
DOI: 10.1093/bfgp/elx001

Jessamy C. Tiffen et al. EZH2 as a mediator of treatment resistance in melanoma, Pigment Cell & Melanoma Research (2016). DOI: 10.1111/pcmr.12481

Related Stories

Epigenetic changes promoting cancer metastasis identified

December 21, 2016
Latest University of Otago research is shedding new light on why and how cancer cells spread from primary tumours to other parts of the body. This phenomenon – known as metastasis – causes about 90 per cent of all cancer ...

Study reveals how melanoma spreads

February 8, 2017
Cancerous tumors are voracious. Once they have consumed all the oxygen and nutrients in the original tumor site, the cancer cells travel to other parts of the body (metastasize) to find more nourishment.

Study identifies potential combination therapy for ovarian cancer

October 28, 2016
A new study has identified an effective combination therapy for treating ovarian cancer cells.

Scientists find three subgroups in a children's brain cancer, identify druggable targets

December 12, 2016
Multi-institutional researchers investigating an incurable brain cancer in children have discovered three distinct subgroups of disease and identified promising drugs to target each type.

Researchers define how cancer cell of origin controls invasive and metastatic properties of tumor cells

November 24, 2016
Researchers at the Université libre de Bruxelles, ULB define for the first time how the cancer cell of origin controls invasive and metastatic properties of tumor cells.

Study finds breast and ovarian cancer may have similar origins

May 23, 2016
While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. These facts reflect the continued ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.